💬In plain words
What the trial is, and whether it could suit you
This example Phase 1 study is designed to evaluate the safety, tolerability, feasibility, and preliminary anti-tumor activity of ETB-DualNK-01, an allogeneic dual-target PSMA/PSCA CAR-NK cell therapy, in adults with metastatic castration-resistant prostate cancer (mCRPC). Part A uses dose escalation to determine the maximum tolerated dose and/or recommended Phase 2 dose. Part B expands at the selected dose in biomarkerconfirmed disease.
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
* Male participant age 18 years or older.
* Histologically or cytologically confirmed prostate adenocarcinoma with metastatic castration-resistant disease.
* Disease progression by PCWG3 while maintaining castrate testosterone (\<50 ng/dL) with ongoing androgen deprivation therapy or prior orchiectomy.
* Documented PSMA and/or PSCA expression by a validated tumor assay; PSMA PET may support target confirmation when applicable.
* Prior progression on at least one androgen receptor pathway inhibitor such as abiraterone, enzalutamide, apalutamide, or darolutamide; prior taxane, PARP inhibitor, radioligand therapy, or checkpoint inhibitor is allowed.
* ECOG performance status 0 or 1.
* Adequate hematologic, renal, hepatic, cardiac, and pulmonary function per protocol laboratory thresholds.
* At least one measurable lesion by RECIST 1.1 or evaluable bone-predominant disease by PCWG3.
* Life expectancy of at least 12 weeks.
* Ability to understand and sign informed consent and willingness to provide required blood and tissue samples.
Exclusion Criteria:
* Active central nervous system metastases or leptomeningeal disease.
* Dominant small-cell or neuroendocrine prostate cancer histology.
* Prior gene-modified cellular therapy within 6 months before lymphodepletion, or prior allogeneic transplant requiring ongoing systemic immunosuppression.
* Active autoimmune disease requiring systemic treatment or chronic immunosuppression; systemic corticosteroid use greater than 10 mg prednisone equivalent daily within 7 days of lymphodepletion.
* Uncontrolled infection, including uncontrolled hepatitis B, hepatitis C, or HIV infection.
* Clinically significant cardiovascular disease, symptomatic arrhythmia, recent myocardial infarction, or uncontrolled heart failure.
* Unresolved grade 2 or higher toxicity from prior anticancer therapy, except alopecia, stable endocrinopathy, or other protocol-approved exceptions.
* Another active malignancy requiring systemic treatment.
* Any medical, psychiatric, or laboratory abnormality that, in the investigator's judgment, would increase risk or interfere with study interpretation.
HealthTeky